Based on the pre-clinical data previously discussed (80), the combination of the CHK1 inhibitor MK-8776 with cytarabine was evaluated in a phase 1 trial in relapsed or refractory AML. The gene discussed is CHEK1; the disease is acute myeloid leukemia.